Thrombophilia-associated pregnancy wastage

Fertility and Sterility

Volumn 72, Issue 5, 1999, Pages 765-774

  Blumenfeld, Zeev ^a   Brenner, Benjamin ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Anticardiolipin; Antithrombin III; Factor II; Factor V Leiden; Hyperhomocysteinemia; MTHFR; Pregnancy wastage; Protein C; Protein S; Thrombophilia

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; GLUCOCORTICOID; HEPARIN; IMMUNOGLOBULIN;

ACTIVATED PROTEIN C RESISTANCE; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONTROLLED STUDY; FETUS WASTAGE; HUMAN; HYPERHOMOCYSTEINEMIA; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; SPONTANEOUS ABORTION; THROMBOPHILIA; THROMBOSIS;

EID: 0032746068     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(99)00360-X     Document Type: Review

References (100)

1. Lockshin M.D. Lupus pregnancy. Clin Rheum Dis. 11:1985;611-632.
2. Haywood L., Brown M.D. Antiphospholipid antibodies and recurrent pregnancy loss. Clin Obstet Gynecol. 34:1991;1-17.
3. Blumenfeld Z., Weiner Z., Lorber M., Sujov P., Thaler I. Anticardiolipin antibodies in patients with recurrent pregnancy wastage treatment and uterine blood flow . Obstet Gynecol. 78:1991;584-589.
4. Ashershon R.A., Khamashtama M.A., Ordi-Ros J. The "primary" antiphospholipid syndrome major clinical and serological features . Medicine (Baltimore). 68:1989;366-377.
5. Laskin C.A., Bombardier C., Hannah M.E., Mandel F.P., Know Ritchie J.W., Farewell V., et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med. 337:1997;148-153.
6. Lockshin M.D., Druzin M.I., Goei S., Qamar T., Magid M.S., Jovanovich L., et al. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med. 313:1985;152-156.
7. Lane D.A., Mannucci P.M., Bauer K.A., Bertina R.M., Bochkov N.P., Boulyjenkov V., et al. Inherited thrombophilia part 1 . Thromb Haemost. 76:1996;651-662.
8. Lane D.A., Mannucci P.M., Bauer K.A., Bertina R.M., Bochkov N.P., Boulyjenkov V., et al. Inherited thrombophilia part 2 . Thromb Haemost. 76:1996;824-834.
9. Ridker P.M., Hennekens C.H., Lindpaintner K., Stampfer M.J., Eisenberg P.R. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 332:1995;912-917.
10. Brenner B., Blumenfeld B. Thrombophilia and fetal loss. Blood Rev. 97:1997;551-554.
11. Scott J.R., Rote N.S., Branch D.W. Immunologic aspects of recurrent abortions and fetal death. Obstet Gynecol. 70:1987;645-656.
12. Branch D.W., Scott J.R., Kochenour N.K., Hershgold M. Obstetric complications associated with the lupus anticoagulant. N Engl J Med. 313:1985;1322-1326.
13. Kochenour N.K., Branch D.W., Rote N.S., Scott J.R. A new postpartum syndrome associated with antiphospholipid antibodies. Obstet Gynecol. 69:1987;460-468.
14. Harris E.N., Gharavi A.E., Boey M.L., Patel B.M., Mackwarth-Young C.G., Luizom S., et al. Anticardiolipin antibodies detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus . Lancet. 2:1983;1211-1214.
15. Pattison N.S., Mekay E.J., Liggins G.C., Lubbe W.F. Anticardiolipin antibodies their presence as a marker for lupus anticoagulant in pregnancy . N Z Med J. 100:1987;61-66.
16. Triplett D.A. Antiphospholipid antibodies proposed mechanisms of action . Am J Reprod Immunol. 28:1992;211-215.
17. Triplett D.A., Brandt J.T., Musgrave K.A., Orr C.A. The relationship between lupus anticoagulant and antibodies to phospholipid. J Am Med Assoc. 259:1988;550-554.
18. Lockshin M.D., Qamar T., Druzin M.L., Goei S. Antibody to cardiolipin, lupus anticoagulant and fetal death. J Rheumatol. 14:1987;259-262.
19. Yetman D.L., Kutteh W.H. Antiphospholipid antibody panels and recurrent pregnancy loss prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies . Fertil Steril. 66:1996;540-546.
20. Kutteh W.H., Lyda L.E., Abraham S.M., Wacholtz M.C. Association of anticardiolipin antibodies and pregnancy loss in women with systemic lupus erythematosus. Fertil Steril. 60:1993;449-455.
21. Weiner Z., Lorber M., Blumenfeld Z. Umbilical and uterine artery flow velocity waveforms in pregnant women with systemic lupus erythematosus treated with aspirin and glucocorticosteroids. Am J Reprod Immunol. 28:1992;168-171.
22. Simpson J.L., Larson S.A., Chesney C., Lanley M.R., Metzger B., Aarons J., et al. Lack of association between antiphospholipid antibodies and first trimester spontaneous abortion prospective study of pregnancies detected within 21 days of conception . Fertil Steril. 69:1998;814-820.
23. Cowchock S. Autoantibodies and pregnancy loss. N Engl J Med. 337:1997;197-198.
24. Rebar G., Arvieux J., Comby E., Degenne D., de Moerloose P., Sammarco M., et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. The Working Group on Methodologies in Haemostasis from the GEHT (Groupe d'Etudes sur l'Hemostast et la thrombose). Thromb Haemost. 73:1995;444-452.
25. Abuaf N., Meyer O., Laperche S., Pierron D., Laroche P., Rajoely B., et al. Conclusions du 1st atelier francais de standardisation du dosage des anticorps anticardiolipine associès à la pathologie autoimmune. Ann Biol Clin (Paris). 52:1994;365-373.
26. Vila P., Hernandez M.C., Lopez-Fernandez M.F., Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost. 72:1994;209-213.
27. Brenner B., Sarig G., Weiner Z., Younis Y., Blumenfeld Z., Lanir N. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost. 82:1999;6-9.
28. Rand J.H., Wu X.-X., Andree H.A.M., Lockwood C.J., Guller S., Scher J., et al. Pregnancy loss in the antiphospholipid-antibody syndrome - a possible thrombogenic mechanism. N Engl J Med. 337:1997;154-160.
29. Gris J.C., Schved J.F., Neveu S., Aguilar-Martinez P., Dupaigne D., Mares P. Impaired fibrinolytic capacity and early recurrent spontaneous abortions. Br Med J. 300:1990;1500.
30. Gris J.C., Neveu S., Mares P., Biron C., Schved J.F. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortions of unknown etiology. J Lab Clin Med. 122:1993;606-615.
31. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thrombosis et Diathesis Haemorrhagica. 13:1965;516-520.
32. Griffin J.H., Evart B., Zimmerman T.S., Kleiss A.J., Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 68:1981;1370-1373.
33. Dahlbäck B. Inherited thrombophilia resistance to activated protein C as a pathogenic factor of venous thromboembolism . Blood. 85:1995;607-614.
34. Dahlbäck B., Carlsson M., Svensson P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C prediction of a cofactor to activated protein C . Proc Natl Acad Sci USA. 90:1993;1004-1008.
35. Bertina R.M., Koeleman B.P.C., Koster T., Rosendaal F.R., Dirven R.J., de Ronde H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 369:1994;64-67.
36. Rees D.C., Cox M., Clegg J.B. World distribution of factor V Leiden. Lancet. 346:1995;1133-1134.
37. 506-Gln mutation of factor V gene . Thromb Haemost. 75:1996;522-523.
38. Zivelin A., Griffin J.H., Xu X., Pabinger I., Samama M., Conard J., et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood. 89:1997;397-402.
39. Griffin J.H., Evart B., Wideman C., Fernández J.A. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood. 82:1993;1989-1994.
40. Svensson P.J., Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 330:1994;517-522.
41. Hellgren M., Svensson P.J., Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 173:1995;210-213.
42. Vandenbroucke J.P., Koster T., Briet E., Reitsma P.H., Bertina R.M., Rosendaal F.R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 344:1994;1453-1457.
43. Ehrenforth S., Radtke K.P., Scharrer I. Acquired activated protein C resistance in patients with lupus anticoagulants. Thromb Haemost. 74:1995;797-798.
44. Borrell M., Sala N., de Castellarnau C., Lopez S., Gari M., Fontcuberta J. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemost. 68:1992;268-272.
45. Rai R., Regan L., Hadley E., Dave M., Cohen H. Second trimester pregnancy loss is associated with activated protein C resistance. Br J Haematol. 92:1996;489-490.
46. Preston F.E., Rosendaal F.R., Walker I.D., Briët E., Berntorp E., Conard J., et al. Increased fetal loss in women with heritable thrombophilia. Lancet. 348:1996;913-916.
47. Brenner B., Mandel H., Lanir N., Younis J., Rothbart H., Ohel G., et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol. 97:1997;551-554.
48. Brenner B., Lanir N., Thaler I. HELLP syndrome associated with factor V R506Q mutation. Br J Haematol. 92:1996;999-1001.
49. Infante-Rivard C., David M., Gauthier R., Rivard G.E. Lupus anticoagulants, anticardiolipin antibodies and fetal loss. N Engl J Med. 325:1991;1063-1066.
50. Grandone E., Margaglione M., Colaizzo D., d'Addedda M., Cappucci G., Vecchione G. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost. 77:1997;822-824.
51. Ridker P.M., Miletich J.P., Buring J.E., Ariyo A.A., Price D.T., Manson J.E., et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med. 128:1998;1000-1003.
52. Sanson B.J., Friederich P.W., Simioni P., Zanardi S., Huisman M.V., Girolami A., et al. The risk of abortion and stillbirth in antithrombin, protein C, and protein S-deficient women. Thromb Haemost. 75:1996;387-388.
53. Girling J., de Swiet M. Inherited thrombophilia and pregnancy. Curr Opin Obstet Gynecol. 10:1998;135-144.
54. Bauters A., Zawadzki C., Bura A., Watel A., Subtil D., Aiach M., et al. Homozygous variant of antithrombin with lack of affinity for heparin management of severe thrombotic complications associated with fetal demise . Blood Coagul Fibrinolysis. 7:1996;705-710.
55. De Stefano V., Finazzi G., Mannucci P.M. Inherited thrombophilia pathogenesis, clinical syndromes and management . Blood. 87:1996;3531-3544.
56. Goodwin T.M. Congenital hypofibrinogenemia in pregnancy. Obstet Gynecol Surv. 44:1989;157-161.
57. Haverkate F., Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC subcommittee on fibrinogen. Thromb Haemost. 73:1995;151-161.
58. Egbring R., Kroniger A., Seitz R. Factor XIII deficiency pathogenetic mechanisms and clinical significance . Semin Thromb Hemost. 22:1996;419-425.
59. Rosenblatt DS. Inherited disorders of folate transport and metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle DL, eds. The metabolic and molecular bases of inherited disease. 7th ed. Vol. 2. New York: McGraw-Hill, 1995:3111-28.
60. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle DL, eds. The metabolic and molecular bases of inherited disease. 7th ed. Vol. 2. New York: McGraw-Hill, 1995:1279-327.
61. Selhub J., Jacques P.F., Wilson P.W., Rush D., Rosenberg I.H. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. J Am Med Assoc. 270:1993;2693-2698.
62. Chambers J.C., McGregor A., Jean-Marie J., Kooner J.S. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet. 351:1998;36-37.
63. Molloy A.M., Daly S., Mills J.L., Kirke P.N., Whitehead A.S., Ramsbottom D., et al. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red cell folates implications for folate intake recommendations . Lancet. 349:1997;1591-1593.
64. Kluijtmans L.A.J., van den Heuvel L.P.W.J., Boers G.H.J., Frosst P., Stevens E.M.B., van Oost B.A., et al. Molecular genetic analysis in mild hyperhomocysteinemia a common mutation in the methylene-tetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease . Am J Hum Genet. 58:1996;35-41.
65. Stampfer M.J., Malinow M.R., Willett W.C., Newcomer L.M., Upson B., Ulhmann D., et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. J Am Med Assoc. 268:1993;877-881.
66. Ma J., Stampfer M.J., Hennekens C.H., Frosst P., Selhub J., Horsford J., et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation. 94:1996;2410-2416.
67. Guttormsen A.B., Ueland P.M., Nesthus I., Nygärd O., Schneede J., Vollset S.E., et al. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (≥40 μmol/liter). J Clin Invest. 98:1996;2174-2183.
68. Steegers-Theunissen R.P.M., Boers G.H.J., Trijbels F.J.M., Finkelstein J.D., Blom H.J., Thomas C.M.G., et al. Maternal hyperhomocysteinemia a risk factor for neural-tube defects? Metabolism. 43:1994;1475-1480.
69. Den Heijer M., Koster T., Blom J.H., Bos G.M.J., Briet E., Reitsma P.H., et al. Hyperhomocysteinaemia as a risk factor for deep vein thrombosis. N Engl J Med. 334:1996;759-762.
70. Den Heijer M., Blom H.J., Gerrits W.B.J., Rosendaal F.R., Haak H.L., Wijermans P.W., et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet. 345:1995;882-885.
71. Nelen W.L.D.M., Steegers E.A.P., Eskes T.K.A.B., Blom J.H. Genetic risk factor for unexplained recurrent early pregnancy loss. Lancet. 350:1997;861.
72. Nelen W.L.D.M., van der Molen E.F., Blom H.J., Heil S.G., Steegers E.A.P., Eskes T.K.A.B. Recurrent early pregnancy loss and genetic-related disturbances in folate and homocysteine metabolism. Br J Hosp Med. 58:1997;511-513.
73. Dekker G.A., de Vries J.I.P., Doelitzsch P.M., Huijgens P.C., von Blomberg B.M.E., Jakobs C., et al. Underlying disorders associated with severe early onset preeclampsia. Am J Obstet Gynecol. 173:1995;1042-1048.
74. de Vries J.I.P., Dekker G.A., Huijgens P.C., Jakobs C., Blomberg B.M.E., van Geijn H.P. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol. 104:1997;1248-1254.
75. Poort S.W., Rosendall F.R., Reitsma P.H., Bertina R.M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 88:1996;3698-3703.
76. Rosendaal F.R., Doggen C.J., Zivelin A., Arruda V.R., Aiach M., Siscovick D.S., et al. Geographic distribution of the 20210G to a prothrombin variant. Thromb Haemost. 79:1998;706-708.
77. Koeleman B.P.C., Reitsma P.H., Allaart C.F., Bertina R.M. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood. 84:1994;1031-1036.
78. Gandrille S., Greengard J.S., Alhenc-Gelas M., Juhan-Vague I., Abgrall J.F., Jude B., et al. Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C deficient patients. Blood. 86:1995;219-225.
79. Brenner B., Zivelin A., Lanir N., Greengard J.S., Griffin J.H., Seligsoh U. Venous thromboembolism associated with double heterozygosity for R506Q mutation of factor V and for T298M mutation of protein C in a large family of a previously described homozygous protein C deficient newborn with massive thrombosis. Blood. 88:1996;877-880.
80. Zöller B., Berntsdotter A., García de Frutos P., Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood. 85:1995;3518-3519.
81. Mandel H., Brenner B., Berant M., Rosenberg N., Lanir N., Jakobs C., et al. Coexistence of hereditary homocysteinuria and factor V Leiden - effect on thrombosis. N Engl J Med. 334:1996;763-768.
82. Brenner B., Vulfsons S.L., Lanir N., Nahir M. Coexistence of familial antiphospholipid syndrome and factor V Leiden - impact on thrombotic diathesis. Br J Haematol. 94:1996;166-167.
83. Saleh A.A., Bottoms S.F., Welch R.A., Ali A.M., Mariona F.G., Mammen E.F. Preeclampsia, delivery, and the hemostatic system. Am J Obstet Gynecol. 157:1987;331-336.
84. Brenner B., Zwang E., Bronshtein M., Seligsohn U. von Willebrand factor multimer patterns in pregnancy induced hypertension. Thromb Haemost. 62:1989;715-717.
85. Dizon-Townson D.S., Nelson L.M., Katrina Easton B.S., Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol. 155:1996;902-905.
86. Grandone E., Margaglione M., Colaizzo D., Cappucci G., Paladini D., Martinelli P., et al. Factor V Leiden, C> MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost. 77:1997;1052-1054.
87. Malia R.G., Kitchen S., Greaves M., Preston F.E. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol. 76:1990;101-107.
88. Healy A.M., Rayburn H.B., Rosenberg R.D., Weiler H. Absence of the blood clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci USA. 92:1995;850-854.
89. Lubbe W.F., Palmer S.J., Butler W.S., Liggins G.C. Fetal survival after prednisone suppression of maternal lupus anticoagulant. Lancet. 1:1983;1361-1363.
90. Salafia C.M., Starzyk K., Lopez-Zeno J., Parke A. Fetal losses and other obstetric manifestations in the antiphospholipid syndrome. Asherson R.A., Cervera R., Piette J.C., Schoenfeld Y. The antiphospholipid syndromes. 1996;117-131 CRC Press, Boca Raton (FL).
91. Elder M.G., de Swiet M., Robertson A., Elder M.A., Flloyd E., Hawkins D.F. Low-dose aspirin in pregnancy. Lancet. 1:1988;410-412.
92. Balasch J., Carmona F., Lopez-Soto A., Font J., Creus M., Fabregues F., et al. Low-dose aspirin for prevention of pregnancy losses in women with primary antiphospholipid syndrome. Hum Reprod. 8:1993;2234-2239.
93. Silver R.K., MacGregor S.N., Sholl J.S., Hobart J.M., Neerhof M.G., Ragin N. A comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am Obstet Gynecol. 169:1993;1411-1417.
94. Cowchock F.S., Reece E.A., Balaban D., Branch J.W., Plouffer L. Repeated fetal losses associated with antiphospholipid antibodies a collaborative randomized trial comparing prednisone to low-dose heparin treatment . Am J Obstet Gynecol. 166:1992;1318.
95. Blank M., Cohen J., Toder V., Shoenfeld Y. Induction of antiphospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anticardiolipin antibodies. Proc Natl Acad Sci USA. 88:1991;3069-3073.
96. Orvieto R., Achiron A., Ben-Rafael Z., Achiron R. Intravenous immunoglobulin treatment for recurrent abortions caused by antiphospholipid antibodies. Fertil Steril. 56:1991;1013-1020.
97. Lima F., Khamashta M.A., Buchanan N.M.M., Kerslake S., Hunt B.J., Hughes G.R.V. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol. 14:1996;131-136.
98. Kutteh W.H. Antiphospholipid antibody-associated recurrent pregnancy loss treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone . Am J Obstet Gynecol. 174:1996;1584-1589.
99. Rai R., Cohen H., Dave M., Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J. 314:1997;253-257.
100. Younis J.S., Ohel G., Brenner B., Ben-Ami M. Familial thrombophilia - the scientific rationale for thrombophylaxis in recurrent pregnancy loss. Hum Reprod. 12:1997;1389-1390.